Lead Discovery Using 3D Cancer Organoids

Le résumé fourni par la source

Despite the recent technological advancements in cancer research, there is still a major challenge to rapidly determine efficient chemotherapeutics to fight it. Traditional high-throughput drug screening was mainly focused on two-dimensional (2D) cell models, that were not physiologically relevant and were inadequately recapitulating the complexity of the tumors in vivo. Major advances in life science technology and oncology have enabled the 3D tissue culture models to be more amenable and affordable for high throughput screening. This yields more predictive compound response profiling for the translation of preclinical studies. These advances have proven that the use of 3D models is an important bridge to close the gap between drug discovery and personalized medicine. New small molecule approaches using 3D cell models have become an essential tool for the evaluation of new drug therapies. Advances by our group have enabled the implementation and screening of 3D models in a rapid and highly cost-effective manner that allows rapid and direct compound response profiling to be generated using a phenotypic approach. Creating these affordable and scalable methods to produce 3D culture models is an important achievement toward precision medicine while also providing novel methodologies for drug discovery.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.